The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial / Rambaldi, Alessandro; Grassi, Anna; Masciulli, Arianna; Boschini, Cristina; Micò, Maria Caterina; Busca, Alessandro; Bruno, Benedetto; Cavattoni, Irene; Santarone, Stella; Raimondi, Roberto; Montanari, Mauro; Milone, Giuseppe; Chiusolo, Patrizia; Pastore, Domenico; Guidi, Stefano; Patriarca, Francesca; Risitano, ANTONIO MARIA; Saporiti, Giorgia; Pini, Massimo; Terruzzi, Elisabetta; Arcese, William; Marotta, Giuseppe; Carella, Angelo Michele; Nagler, Arnon; Russo, Domenico; Corradini, Paolo; Alessandrino, Emilio Paolo; Torelli, Giovanni Fernando; Scimè, Rosanna; Mordini, Nicola; Oldani, Elena; Marfisi, Rosa Maria; Bacigalupo, Andrea; Bosi, Alberto. - In: THE LANCET ONCOLOGY. - ISSN 1470-2045. - 16:15(2015), pp. 1525-1536. [10.1016/S1470-2045(15)00200-4]
Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial
RISITANO, ANTONIO MARIA;
2015
Abstract
The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because the combination of busulfan plus fludarabine has been proposed to reduce non-relapse mortality, we aimed to compare this treatment with busulfan plus cyclophosphamide as a preparative regimen in these patients| File | Dimensione | Formato | |
|---|---|---|---|
|
#97 Rambaldi Lancet Onc 2015.pdf
accesso aperto
Tipologia:
Documento in Post-print
Licenza:
Accesso privato/ristretto
Dimensione
444.52 kB
Formato
Adobe PDF
|
444.52 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
